Clinical Trials on Insulin Resistance, Diabetes in Russian Federation

Total 449 results

Hoffmann-La Roche

Completed

A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment

Diabetes Mellitus Type 2

Australia, Hong Kong, Colombia, Russian Federation, Germany, Hungary, Italy, Mexico, Peru, Romania, Slovakia, Brazil, El Salvador
AstraZeneca
Bristol-Myers Squibb

Completed

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

Type 2 Diabetes

United States, Canada, Mexico, Russian Federation
Sanofi

Completed

Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin

Type 2 Diabetes Mellitus

Spain, United States, Canada, Czech Republic, France, Germany, Poland, Romania, Russian Federation, Ukraine
Mannkind Corporation

Completed

Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal Challenge

Diabetes Mellitus | Upper Respiratory Infection

United States, Russian Federation, Canada
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus (SUSTAIN 9)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Canada, Austria, Japan, Norway, Puerto Rico
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Type 2 Diabetes Mellitus

United States, Brazil, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Turkey, United Kingdom, South Africa, Argentina, Canada, Germany, Hungary, Israel, Romania, Slovakia, India, Belgium, France, Puerto Rico
Boehringer Ingelheim

Completed

12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

Argentina, Croatia, Estonia, Germany, Italy, Korea, Republic of, Lithuania, Romania, Russian Federation, Slovakia, Sweden, Taiwan, Ukraine
Novo Nordisk A/S

Completed

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms (DUAL™ VI)

Diabetes Mellitus, Type 2 | Diabetes

United States, Slovakia, Canada, Austria, Hungary, Serbia, Russian Federation, Bulgaria, Czechia
AstraZeneca
Eli Lilly and Company

Completed

A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Sweden, Italy, Korea, Republic of, Mexico, Russian Federation, Spain, Estonia, Romania, Finland, Netherlands, Argentina, Belgium, Germany, Portugal, United Kingdom, Greece, France, Puerto Rico
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Croatia, Italy, Slovakia, Denmark, Macedonia, The Former Yugoslav Republic of, Norway, Russian Federation, Finland, France, Poland, Greece, Romania, Sweden, Czech Republic, Argentina
Akros Pharma Inc.

Completed

Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients

Type II Diabetes Mellitus

United States, Russian Federation, Czech Republic, Hungary, Netherlands
Sanofi

Completed

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

Type 2 Diabetes Mellitus

Brazil, Peru, United States, Australia, Canada, Chile, Germany, Guatemala, Mexico, Poland, Romania, Russian Federation, Ukraine
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Nutritional and Metabolic Diseases

United Kingdom, Germany, Belgium, Poland, India, Finland, Sweden, Netherlands, Russian Federation, Norway, Denmark
AstraZeneca

Completed

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Diabetes

United States, United Kingdom, Germany, Hungary, Mexico, Poland, Russian Federation, Romania, Czechia, Sweden
Mannkind Corporation

Completed

Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States, Russian Federation, Brazil, Ukraine
Mannkind Corporation

Completed

A 2-Month Safety Follow-Up Trial

Type 1 Diabetes | Type 2 Diabetes

United States, Brazil, Canada, Russian Federation
Mannkind Corporation

Completed

Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period

Type 1 Diabetes Mellitus

United States, Brazil, Russian Federation, Ukraine
Novo Nordisk A/S

Completed

Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes (EXPECT)

Diabetes | Diabetes Mellitus, Type 1

Israel, Italy, Russian Federation, United Kingdom, Denmark, Austria, Serbia, Canada, Croatia, Australia, Greece, Ireland, Brazil, Spain, Argentina
Boehringer Ingelheim

Completed

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Australia, Canada, Czech Republic, Russian Federation, Ukraine
Janssen Research & Development, LLC

Completed

An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

Diabetes Mellitus, Type 2

United States, Romania, Canada, Russian Federation, Czech Republic, Slovakia, Mexico
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United Kingdom, Denmark, Canada, France, Netherlands, Austria, Israel, Finland, Russian Federation, Croatia, Bulgaria, Poland, Ireland, Spain, Norway, Greece, Argentina, Germany
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating PPM-204 In Subjects With Type 2 Diabetes

Diabetes Mellitus

China, United States, Canada, Mexico, Russian Federation, Croatia, United Kingdom, Argentina, Australia, India, South Africa, Greece, Ukraine, Romania, Italy, Hong Kong, Former Serbia and Montenegro, Brazil
Novo Nordisk A/S

Completed

Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Spain, Russian Federation, Turkey, Austria, India, Korea, Republic of
Eli Lilly and Company

Completed

A Study in Participants With Type 1 Diabetes Mellitus (IMAGINE 1)

Diabetes Mellitus, Type 1

Japan, United States, Russian Federation, France, Mexico, Austria, Germany, Italy, Poland
AstraZeneca
Bristol-Myers Squibb

Completed

Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin

Type 2 Diabetes

United States, Bulgaria, Russian Federation, United Kingdom, Hungary, Romania, Finland, Canada, Austria, Germany, Netherlands, Slovakia, Spain
Novo Nordisk A/S

Completed

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only (PIONEER 1)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Mexico, Japan, Serbia, Turkey, Italy, Czechia, Bulgaria, Algeria, Romania
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes (SUSTAIN™1)

Diabetes Mellitus, Type 2 | Diabetes

United States, United Kingdom, Mexico, Russian Federation, Japan, Canada, Italy, South Africa, Romania
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, United Kingdom, Spain, Denmark, France, Netherlands, Austria, Hungary, Russian Federation, Germany, Turkey, Italy, Bulgaria, Romania, Belgium, Switzerland, Slovenia, Czech Republic
Novo Nordisk A/S

Completed

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Israel, Russian Federation, Puerto Rico, United Arab Emirates, Brazil
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Spain, Hungary, Mexico, Slovakia, Greece, Argentina, South Africa, Australia
Sanofi

Completed

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine (GetGoal-Duo1)

Type 2 Diabetes Mellitus

United States, Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Estonia, France, Germany, Hungary, India, Israel, Italy, Malaysia, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russian Federation, South Africa, Swed... and more
Eli Lilly and Company

Completed

A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes (PRONTO-T2D)

Type 2 Diabetes Mellitus

United States, Hungary, Puerto Rico, Spain, Australia, Korea, Republic of, Mexico, Japan, Germany, Russian Federation, Taiwan, Slovakia, Argentina, Czechia, India, Italy
AstraZeneca
Bristol-Myers Squibb

Completed

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

Type 2 Diabetes Mellitus

Korea, Republic of, United States, Mexico, India, Puerto Rico, Russian Federation
Novartis

Completed

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)

Diabetes Mellitus, Type 2 | Renal Insufficiency

Spain, Canada, France, Germany, Australia, Costa Rica, Finland, Russian Federation, Argentina, India, Norway, Sweden
Russian Federation of Anesthesiologists and Reanimatologists
Kuban State Medical University

Recruiting

The Role of Concomitant Diseases in Postoperative Complications Risk Stratification. (STOPRISK)

Stroke | Epilepsy | Diabetes | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Neuromuscular Diseases | Parkinson's Disease | Anemia | Coronary Heart Disease | Chronic Heart Failure | Alzheimer's Disease | Bronchial Asthma | Heart Rhythm Disorders

Russian Federation
Ionis Pharmaceuticals, Inc.

Completed

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Castrate-Resistant Prostate Cancer

United States, Puerto Rico, Hungary, Romania, Russian Federation, Poland
Marinus Pharmaceuticals

Completed

Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension

Drug Resistant Partial Onset Seizure

United States, Australia, Russian Federation, Bulgaria, Germany, Poland
AstraZeneca
Bristol-Myers Squibb

Completed

Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

Type 2 Diabetes

Croatia, United States, Bulgaria, Czech Republic, Poland, Russian Federation, Belarus, Estonia, Germany, Hungary, Latvia, Lithuania, Romania, Ukraine
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST 2)

Diabetes Mellitus, Type 2 | Dyslipidemia | Peripheral Vascular Disease | Coronary Arteriosclerosis | Cerebrovascular Accident

Greece, Ireland, Russian Federation, Slovakia, Poland, Hungary, Portugal, Switzerland
AstraZeneca
Bristol-Myers Squibb

Completed

52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period

Type 2 Diabetes

Korea, Republic of, Russian Federation, United Kingdom, Vietnam, Germany, Hungary, Finland, Norway, Netherlands, Slovakia, India
Novo Nordisk A/S

Recruiting

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (PIONEER TEENS)

Diabetes Mellitus, Type 2

United States, Malaysia, United Kingdom, Australia, Netherlands, Portugal, Austria, Israel, India, Greece, Lebanon, Mexico, New Zealand, North Macedonia, Puerto Rico, Romania, Russian Federation, Ukraine, Morocco, Belgium, Czechia, Taiw...
Novo Nordisk A/S

Completed

Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus (PIONEER 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, Italy, Poland, Russian Federation, Spain, Greece, Serbia, Thailand, Brazil, Hungary, Argentina
Novo Nordisk A/S

Completed

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes (LEAD-5)

Diabetes Mellitus, Type 2 | Diabetes

Italy, Poland, Denmark, France, Netherlands, Austria, Spain, Finland, Argentina, India, Russian Federation, United Kingdom, Slovakia, Brazil, Norway, Former Serbia and Montenegro, South Africa, Philippines
Novo Nordisk A/S

Completed

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

Germany, France, United States, Japan, Netherlands, Russian Federation, Bulgaria, United Kingdom, North Macedonia, South Africa, Italy, Finland
Takeda

Completed

Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.

Type 2 Diabetes Mellitus

United States, Australia, Brazil, Bulgaria, Chile, Croatia, Estonia, Guatemala, India, Israel, Latvia, Mexico, New Zealand, Peru, Romania, Russian Federation, Serbia, South Africa, Ukraine
Novartis Pharmaceuticals

Completed

Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure

Type II Diabetes Mellitus | Congestive Heart Failure

Russian Federation, Singapore, Italy, Czechia, Lithuania, Germany, Guatemala, India, Denmark, Estonia, Slovakia, Romania, Latvia, Greece, Poland
Eli Lilly and Company

Completed

A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus (IMAGINE 5)

Diabetes Mellitus, Type 2

United States, Germany, Israel, Czechia, Spain, Russian Federation, Romania, Puerto Rico, Greece
Sanofi

Completed

Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment (LANCELOT)

Diabetes Mellitus, Type 2

Brazil, Thailand, Slovakia, Poland, Netherlands, Kuwait, Mexico, Korea, Republic of, Czech Republic, Egypt, France, Italy, Romania, Russian Federation, Sweden, Switzerland, United Arab Emirates
AstraZeneca
Bristol-Myers Squibb

Completed

An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

Type 2 Diabetes

Korea, Republic of, United States, Mexico, Puerto Rico, Philippines, Russian Federation, Ukraine
Gilead Sciences

Completed

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

Type 2 Diabetes Mellitus

United States, Russian Federation, Israel, South Africa, India, Hungary, Ukraine, Canada, Czech Republic, Mexico, Poland

Clinical Trials on Insulin Resistance, Diabetes in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations